1. Home
  2. TOP vs RNTX Comparison

TOP vs RNTX Comparison

Compare TOP & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TOP Financial Group Limited

TOP

TOP Financial Group Limited

N/A

Current Price

$1.15

Market Cap

43.0M

Sector

Finance

ML Signal

N/A

RNTX

Rein Therapeutics Inc.

BUY

Current Price

$1.55

Market Cap

38.9M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
TOP
RNTX
Founded
2015
2001
Country
Singapore
United States
Employees
N/A
N/A
Industry
Investment Bankers/Brokers/Service
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
43.0M
38.9M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
TOP
RNTX
Price
$1.15
$1.55
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
46.8K
234.4K
Earning Date
01-26-2026
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$3,329,256.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.00
$1.04
52 Week High
$3.33
$3.50

Technical Indicators

Market Signals
Indicator
TOP
RNTX
Relative Strength Index (RSI) 54.02 58.01
Support Level $1.10 $1.34
Resistance Level $1.24 $1.58
Average True Range (ATR) 0.05 0.10
MACD 0.02 0.01
Stochastic Oscillator 59.09 87.50

Price Performance

Historical Comparison
TOP
RNTX

About TOP TOP Financial Group Limited

TOP Financial Group Ltd is an online brokerage firm in Hong Kong specializing in trading local and overseas equities, futures, and options products. The Company generates brokerage commission income by enabling its customers to trade on multiple exchanges present globally. The company operates in only one segment which is the futures brokerage service.

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.

Share on Social Networks: